ScTIL210 / Chineo Medical Technology, Beijing Cancer Hospital - LARVOL DELTA

A Clinical Study to Observe the Safety and Efficacy of ScTIL210 in the Treatment of Malignant Solid Tumors (clinicaltrials.gov) - P1/2 | N=58 | Recruiting | Sponsor: Shanghai East Hospital | Trial completion date: Dec 2022 ➔ Dec 2024 | Trial primary completion date: Dec 2021 ➔ Dec 2023

Trial completion date • Trial primary completion date • Gastrointestinal Cancer • Oncology • Solid Tumor • CD19 • PD-1

Phase Ib Clinical Study on the Safety, the Tolerability, the Pharmacokinetics and the Efficacy of ScTIL Injection (Gene Modified Tumor Infiltrating Lymphocytes) Alone and in Combination With B Lymphocyte Adjuvant in the Treatment of Digestive System Malignant Solid Tumors (clinicaltrials.gov) - P1 | N=48 | Not yet recruiting | Sponsor: Peking University

Combination therapy • New P1 trial • Cholangiocarcinoma • Colorectal Cancer • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • PD-1

Clinical Study on the Safety, Pharmacokinetics, and Efficacy of ScTIL (Genetically Modified Tumor Infiltrating Lymphocytes) in the Treatment of Gynecological Malignancies (clinicaltrials.gov) - P2a | N=30 | Not yet recruiting | Sponsor: Peking Union Medical College Hospital

New P2a trial • Cervical Cancer • Gastrointestinal Cancer • Gynecologic Cancers • Oncology • Ovarian Cancer • Refractory Ovarian Cancer • Solid Tumor • CD19

A Clinical Study to Observe the Safety and Efficacy of ScTIL210 in the Treatment of Malignant Solid Tumors (clinicaltrials.gov) - P1/2; N=58; Recruiting; Sponsor: Shanghai East Hospital; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Gastrointestinal Cancer • Oncology • Solid Tumor • CD19 • PD-1

A Clinical Study to Observe the Safety and Efficacy of ScTIL210 in the Treatment of Malignant Solid Tumors (clinicaltrials.gov) - P1/2; N=58; Not yet recruiting; Sponsor: Shanghai East Hospital

Clinical • New P1/2 trial • Gastrointestinal Cancer • Oncology • Solid Tumor • CD19 • PD-1

The Tolerance,Pharmacokinetic Characteristics,Safety and Efficacy of ScTIL210 in the Treatment of Melanoma (clinicaltrials.gov) - P1; N=32; Not yet recruiting; Sponsor: Beijing Cancer Hospital

Clinical • New P1 trial